Translate
About
Camurus Ab (OTCGREY:CAMRF) — investor relations, events, news, and company updates on 6ix.
Latest News
Jan 9 2026
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
Nov 10 2025
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
Aug 28 2025
Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK
Jul 1 2025
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Jun 18 2025
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Financials
Revenue
$2.35 B
Market Cap
$3.29 B
P/E Ratio
42.31
EPS
1.30